iMatter2: An Artificial Intelligence (AI)-Driven Approach to Supercharge a Novel Digital Patient-reported Outcomes Tool for Diabetes Management
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Investigators will conduct a hybrid type 1 effectiveness-implementation randomized controlled trial (RCT) to evaluate the effectiveness of iMatter2 versus usual care on reduction in HbA1c at 12-months (primary outcome) among patients with Type 2 diabetes (T2D).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ PCP Group:
• Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers or faculty group practices and
• Provide care to at least five patients with a diagnosis of T2D
⁃ Patient Group:
• Have a diagnosis of T2D for ≥6 months;
• Have uncontrolled T2D defined as HbA1c \>7% documented in the EHR on at least two visits in the past year;
• Fluency in English or Spanish;
• Be willing to send/receive text messages; and
• Be \> 18 years of age.
Locations
United States
New York
NYU Langone Health
RECRUITING
New York
Contact Information
Primary
Priscilla D'antico
Priscilla.D'antico@nyulangone.org
732-501-9057
Time Frame
Start Date: 2025-11-04
Estimated Completion Date: 2028-05-31
Participants
Target number of participants: 353
Treatments
Experimental: iMatter2
All the patients within a primary care provider (PCP) randomized to the intervention will receive iMatter2.
No_intervention: Usual Care (UC)
All patients within PCPs randomized to UC will receive standard Type 2 diabetes (T2D) care by their PCP.
Related Therapeutic Areas
Sponsors
Leads: NYU Langone Health